The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) have been published in the scientific journal Cartilage. The results demonstrate less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM.

Xintela has previously published that integrin α10β1-selected stem cells from horses, EQSTEM, which are the equivalent of the human stem cell product XSTEM®, reduce cartilage and bone damage in a post-traumatic OA model in horses (Delco et al., Am J Sports Med. 2020;48:612). The study results that now have been published in the scientific journal Cartilage, further support a disease modifying effect of EQSTEM by showing significantly less cartilage damage in treated horses compared to untreated horses. In addition, EQSTEM significantly reduced lameness in treated horses which indicates less pain and improved function of the treated joint. The results also demonstrated that specific biological factors were increased in the joint after injection of EQSTEM which provide further understanding of the mechanisms of action of EQSTEM. The study was conducted in collaboration with the University of Copenhagen.

"There is a great need for a treatment that can stop or cure osteoarthritis. Many humans and animals suffer from this disease, while there is no disease modifying drug available. The results of our preclinical study show the potential of our stem cell product to treat osteoarthritis. Treatment with EQSTEM improved joint function and cartilage structure in the horses with post-traumatic osteoarthritis and no side effects of the treatment were observed. The results are also relevant for the treatment of human osteoarthritis patients with our human stem cell product XSTEM and supportive of our ongoing clinical study for the treatment of knee osteoarthritis", says Lucienne Vonk, Xintela's Director of Musculoskeletal Diseases.

The publication:
Integrin α10β1-Selected Mesenchymal Stem Cells Reduce Pain and Cartilage Degradation and Increase Immunomodulation in an Equine Osteoarthritis Model. Camilla Andersen, Stine Jacobsen, Kristina Uvebrant, John F. Griffin, IV, Lucienne Angela Vonk, Marie Walters, Lise Charlotte Berg, Evy Lundgren-Åkerlund, and Casper Lindegaard. Cartilage. 2023. doi: 10.1177/19476035231209402.

Link to the publication: https://journals.sagepub.com/doi/epub/10.1177/19476035231209402

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

Xintela publishes efficacy results with EQSTEM from preclinical equine OA study

© Modular Finance, source Nordic Press Releases